.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,612,208

« Back to Dashboard

Claims for Patent: 7,612,208

Title:Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide or the solvate of the salt and a process for preparing the same
Abstract: A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.
Inventor(s): Matsushima; Tomohiro (Tsukuba, JP), Nakamura; Taiju (Kamisu, JP), Yoshizawa; Kazuhiro (Kamisu, JP), Kamada; Atsushi (Tsukuba, JP), Ayata; Yusuke (Kamisu, JP), Suzuki; Naoko (Ushiku, JP), Arimoto; Itaru (Tokyo, JP), Sakaguchi; Takahisa (Tsukuba, JP), Gotoda; Masaharu (Tsukuba, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:10/577,531
Patent Claims: 1. A crystalline form (Form A) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 9.65.degree. and 18.37.degree. in a powder X-ray diffraction.

2. A crystalline form (Form A) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having peaks at chemical shifts of about 162.4 ppm, about 128.0 ppm, about 102.3 ppm and about 9.9 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

3. A crystalline form (Form A) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having absorption bands at wavenumbers of 1161.+-.1 cm.sup.-1 and 1044.+-.1 cm.sup.-1 in an infrared absorption spectrum.

4. A crystalline form (Form B) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 5.72.degree. and 13.84.degree. in a powder X-ray diffraction.

5. A crystalline form (Form B) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having absorption bands at wavenumbers of 1068.+-.1 cm.sup.-1 and 918.+-.1 cm.sup.-1 in an infrared absorption spectrum.

6. A crystalline form (Form C) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 14.20.degree. and 17.59.degree. in a powder X-ray diffraction.

7. A crystalline form (Form C) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having peaks at chemical shifts of about 160.2 ppm, about 126.6 ppm, about 105.6 ppm and about 7.8 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

8. A crystalline form (Form C) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having absorption bands at wavenumbers of 1324.+-.1 cm.sup.-1 and 579.+-.1 cm.sup.-1 in an infrared absorption spectrum.

9. A crystalline form (Form F) of a hydrate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 8.02.degree. and 18.14.degree. in a powder X-ray diffraction.

10. A crystalline form (Form I) of an acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 9.36.degree. and 12.40.degree. in a powder X-ray diffraction.

11. A crystalline form (Form I) of an acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate having absorption bands at wavenumbers of 1750.+-.1 cm.sup.-1 and 1224.+-.1 cm.sup.-1 in an infrared absorption spectrum.

12. A crystalline form (Form .alpha.) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 15.70.degree. and 17.18.degree. in a powder X-ray diffraction.

13. A crystalline form (Form .alpha.) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate having absorption bands at wavenumbers of 1320.+-.1 cm.sup.-1 and 997.+-.1 cm.sup.-1 in an infrared absorption spectrum.

14. A crystalline form (Form .beta.) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 6.48.degree. and 9.58.degree. in a powder X-ray diffraction.

15. A crystalline form (Form .beta.) of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate having absorption bands at wavenumbers of 1281.+-.1 cm.sup.-1 and 985.+-.1 cm.sup.-1 in an infrared absorption spectrum.

16. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form A), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, methanol and methanesulfonic acid to dissolve.

17. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form A), comprising: mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, acetic acid and methanesulfonic acid to dissolve; and adding ethanol to the mixture.

18. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form B), comprising a step of drying a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form I) at 30.degree. C. for 3 hours and at 40.degree. C. for 16 hours to remove acetic acid.

19. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form C), comprising a step of heating a crystalline form of the dimethyl sulfoxide solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate at 115.degree. C. for 10 hours.

20. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form C), comprising a step of mixing a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form I) and ethanol.

21. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-methoxy-6-quinoline- carboxamide Methanesulfonate (Form C), comprising: mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, acetic acid and methanesulfonic acid to dissolve; and adding 2-propanol to the mixture.

22. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form C), comprising a step of humidifying a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form B).

23. A process for preparing a crystalline form of the hydrate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide methanesulfonate (Form F), comprising: mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, acetic acid and methanesulfonic acid to dissolve and adding ethyl acetate to the mixture.

24. A process for preparing a crystalline form of the acetic acid solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quin- olinecarboxamide methanesulfonate (Form I), comprising: mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, acetic acid and methanesulfonic acid to dissolve; and adding 1-propanol to the mixture.

25. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate (Form .alpha.), comprising a step of mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, dimethyl sulfoxide and ethanesulfonic acid to dissolve.

26. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate (Form .beta.), comprising a step of mixing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate (Form .alpha.) and ethanol.

27. A process for preparing a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide ethanesulfonate (Form .beta.), comprising: mixing 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide, acetic acid and ethanesulfonic acid to dissolve; and adding 2-propanol and water to the mixture.

28. A pharmaceutical composition in the form of a tablet, powder, granule, capsule or lozenge, said pharmaceutical composition comprising the crystalline form according to claim 15; and a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc